Semaglutide: GLP-1 receptor agonist, pioneering the world of divine medicine

    Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk, a leader in the field of diabetes treatment. This drug can stimulate the pancreas β Cells secrete insulin, thereby increasing glucose metabolism; And inhibit the pancreas α Cells secrete glucagon to reduce fasting and postprandial blood sugar. In addition, it can also reduce food intake by reducing appetite and slowing down gastric digestion, ultimately reducing body fat, which is beneficial for weight loss.

    In February 2021, a global large-scale clinical trial published in the NEJM journal showed that subcutaneous injection of 2.4mg of smectide per week resulted in an average weight loss of 15kg. Three quarters of people lose more than 10% of their weight, and over one-third of people lose more than 20% of their weight.

    On March 24, 2023, Novo Nordisk oral version of Smeglutide reached the phase III clinical endpoint. Patients who received a high-dose once daily (50mg) oral administration showed a 2.0% decrease in HbA1c, and a weight loss of 8.0kg after 1 year.

    It can be seen that GLP-1 agonists, represented by Smeglutide, have improved both blood sugar and weight loss, while also transitioning from short-term effects to long-term effects, from injection to oral administration, bringing convenience to patients. It is worth mentioning that GLP-1R agonist is also pursuing cardiovascular benefits, renal protection and other benefits in diabetes patients.